Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of
Although intraductal papillary mucinous neoplasms (IPMNs) represent potential precursors of pancreatic cancer, IPMNs with invasive cancer are rare. Based on current risk factors for malignancy, overtreatment (surgery) of benign IPMNs remains a critical issue, with its associated risk of postoperative and long-term comp
| Condition(s) | IPMN, Pancreatic |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Although intraductal papillary mucinous neoplasms (IPMNs) represent potential precursors of pancreatic cancer, IPMNs with invasive cancer are rare. Based on current risk factors for malignancy, overtreatment (surgery) of benign IPMNs remains a critical issue, with its associated risk of postoperative and long-term complications. Identification of biomarkers that could predict malignancy in IPMNs is an unmet clinical need. Environmental, lifestyle, genetics and metabolic factors may play a role in IPMNs carcinogenesis. Aims of the study are: 1) to analyze exposome, somatic/germline genetic variability, metabolomics and transcriptome profile in order to identify new biomarkers; 2) to use nonparametric epidemiologic approaches and machine learning algorithms to compute a progression score to |
| Who can participate | Inclusion Criteria: * Adult (age \>18 years) patients with a diagnosis of IPMN undergoing and not undergoing surgery * All patients will sign the informed consent For the retrospective patients: * confirmed IPMN diagnosis * signed informed consent for samples biobanking and study participation Exclusion Criteria: * Patients \< 18 years of age * Patients who are not able to supply an informed consent |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | IRCCS San Raffaele |
| Locations | Milan, MI, Italy |
| Start date | 2025-01-03 |
| NCT ID | NCT06694792 |
| Official listing | https://clinicaltrials.gov/study/NCT06694792 |